Keros Therapeutics Inc. (KROS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Lost Money on Keros Therapeutics, Inc.(KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Investors who lost money on Keros Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - KROS
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - KROS
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ATTENTION KROS SHAREHOLDERS: Investors who lost money on Keros Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
KROS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Keros Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
KROS STOCK ALERT: Levi & Korsinsky Notifies Keros Therapeutics, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Investors who lost money on Keros Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - KROS
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS Losses
NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
